Arrowhead Pharmaceuticals FY2026 Results
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced its fiscal year 2026 financial results for the period ended September 30, 2026. The company posted an adjusted loss of $5.11 per share, compared with the Wall Street consensus estimate of a $3.51 loss per share. Revenue for the year was $450.82 million, falling short of the $464.14 million forecast and representing a 46 % decline from the $829.45 million recorded in fiscal 2025. The earnings miss prompted a 2.4 % decline in the stock price in after‑hours trading on Thursday.
Commercially, Arrowhead reported that prescriptions for REDEMPLO, its therapy for familial chylomicronemia syndrome, increased 63 % quarter‑over‑quarter. Cumulative prescriptions reached 950 by the end of the quarter, with an additional 300 prescriptions recorded thereafter. Weekly prescription fills are now approximately 50‑60, and more than 640 unique practitioners have prescribed the product.
Regulatory updates include the submission of a supplemental new‑drug application to the U.S. Food and Drug Administration for plozasiran in severe hypertriglyceridemia. The agency granted Arrowhead entry into its Split Real‑Time Application Review pilot program, which provides a six‑month priority review. Arrowhead is preparing for a potential U.S. launch in the second quarter of 2027, subject to regulatory approval. Phase 3 SHASTA‑3 and SHASTA‑4 trial data showed that plozasiran achieved median triglyceride reductions of 79 % and 81 %, respectively, and lowered acute pancreatitis events by 78 % versus placebo.
Financing activities disclosed that Arrowhead refinanced its credit facility by establishing a $400 million senior secured term loan with Sixth Street. The loan carries an interest rate of SOFR + 5.50 %, a substantial reduction from the prior 15 % rate. As of September 30, 2026, total cash resources stood at $1.19 billion.
Christopher Anzalone, President and Chief Executive Officer, stated that the company has transitioned from relying solely on scientific promise to beginning to translate that promise into tangible patient outcomes and potential durable shareholder value growth.